How much do paid clinical trials in Fayetteville pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Are clinical trials in Fayetteville safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Fayetteville, NC?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

What is the difference between a research center and a hospital study in Fayetteville?

Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

How often do new paid studies open in Fayetteville?

Constantly — trials open and close enrollment every week. This page is refreshed weekly from the NIH registry. Join the email alert to be notified when a new study opens within 30 miles of Fayetteville.

Paid Clinical Trials Fayetteville, NC — 115 Studies Recruiting (Jul 2026)

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung Phase 2 Interventional 130 participants sought

FirstHealth of the Carolinas — Pinehurst, North Carolina (28.8 mi) · Sponsor: Johnson & Johnson Enterprise Innovation Inc.

See eligibility & contact on ClinicalTrials.gov (NCT06667908)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Phase 2 Interventional 150 participants sought

FirstHealth of the Carolinas- Speciality Center /ID# 272924 — Pinehurst, North Carolina (28.8 mi) · Sponsor: AbbVie

See eligibility & contact on ClinicalTrials.gov (NCT06568939)

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus Phase 2 Interventional 405 participants sought

Cross Creek Medical Clinic, PA — Fayetteville, North Carolina (6.0 mi) · Sponsor: Boehringer Ingelheim

See eligibility & contact on ClinicalTrials.gov (NCT07409181)

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer Phase 3 Interventional 1,123 participants sought

FirstHealth of the Carolinas ( Site 6037) — Pinehurst, North Carolina (28.8 mi) · Sponsor: Merck Sharp & Dohme LLC

See eligibility & contact on ClinicalTrials.gov (NCT06952504)

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Posttraumatic Headache, Mild Traumatic Brain Injury Phase 2 Interventional 404 participants sought

Womack Army Medical Center - Fort Liberty — Fort Bragg, North Carolina (4.1 mi) · Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

See eligibility & contact on ClinicalTrials.gov (NCT05049057)

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Asthma Phase 2 Interventional 540 participants sought

Research Site — Pinehurst, North Carolina (28.8 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06932263)

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Prostate Cancer (Adenocarcinoma) Phase 3 Interventional 830 participants sought

FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina (28.8 mi) · Sponsor: Canadian Cancer Trials Group

See eligibility & contact on ClinicalTrials.gov (NCT06592924)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC) Phase 3 Interventional 750 participants sought

FirstHealth Cancer Center — Pinehurst, North Carolina (28.8 mi) · Sponsor: Amgen

See eligibility & contact on ClinicalTrials.gov (NCT05920356)

Empowering Young Parents: Building Healthy Relationships Study

Gender-based Violence, Intimate Partner Violence N/A Interventional 600 participants sought

Empowering Connections, Partnership for Children & Families — Sanford, North Carolina (29.6 mi) · Sponsor: RTI International

See eligibility & contact on ClinicalTrials.gov (NCT06576193)

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis, MASH With Fibrosis Phase 3 Interventional 1,650 participants sought

Akero Clinical Study Site — Fayetteville, North Carolina (6.0 mi) · Sponsor: Akero Therapeutics, Inc

See eligibility & contact on ClinicalTrials.gov (NCT06215716)

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Acute Coronary Syndrome Phase 3 Interventional 2,000 participants sought

Research Site — Pinehurst, North Carolina (28.8 mi) · Sponsor: DalCor Pharmaceuticals

See eligibility & contact on ClinicalTrials.gov (NCT05918861)

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

APOL1-Mediated Kidney Disease Phase 2 Interventional 136 participants sought

Research Site — Fayetteville, North Carolina (6.0 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06824987)

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Endometrial Cancer Phase 3 Interventional 710 participants sought

FirstHealth of the Carolinas, Inc. — Pinehurst, North Carolina (28.8 mi) · Sponsor: Daiichi Sankyo

See eligibility & contact on ClinicalTrials.gov (NCT07022483)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought

FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina (28.8 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04267848)

Shield Post-Approval Study Protocol

Colo-rectal Cancer N/A Observational 3,375 participants sought

Pinehurst Medical Clinic — Pinehurst, North Carolina (28.8 mi) · Sponsor: Guardant Health, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT06880055)

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast Cancer Phase 3 Interventional 4,220 participants sought

Cape Fear Valley Medical Center — Fayetteville, North Carolina (6.0 mi) · Sponsor: Stemline Therapeutics, Inc.

See eligibility & contact on ClinicalTrials.gov (NCT06492616)

Scheduled or As Needed Pain Regimen?

Pain, Postoperative Phase 4 Interventional 90 participants sought

Cape Fear Valley Medical Center — Fayetteville, North Carolina (6.0 mi) · Sponsor: Cape Fear Valley Health System

See eligibility & contact on ClinicalTrials.gov (NCT06495632)

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 1,524 participants sought

FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina (28.8 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT06876714)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought

FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina (28.8 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03851445)

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Chronic Idiopathic Constipation (CIC) Phase 3 Interventional 692 participants sought

Coastal Research Institute, LLC — Fayetteville, North Carolina (6.0 mi) · Sponsor: Ardelyx

See eligibility & contact on ClinicalTrials.gov (NCT07382167)

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Interventional 990 participants sought

Research Site — Fayetteville, North Carolina (6.0 mi) · Sponsor: AstraZeneca

See eligibility & contact on ClinicalTrials.gov (NCT06878261)

Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms

PTSD, Cognitive Performance N/A Interventional 120 participants sought

Fort Bragg — Fayetteville, North Carolina (6.0 mi) · Sponsor: Ohio State University

See eligibility & contact on ClinicalTrials.gov (NCT07680517)

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or Overweight Phase 3 Interventional 290 participants sought

Coastal Research Institute - Fayetteville — Fayetteville, North Carolina (6.0 mi) · Sponsor: Eli Lilly and Company

See eligibility & contact on ClinicalTrials.gov (NCT06937099)

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma Phase 2, Phase 3 Interventional 992 participants sought

FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina (28.8 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05987241)

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis Phase 3 Interventional 671 participants sought

Cross Creek Medical Clinic - Site Number: 8400057 — Fayetteville, North Carolina (6.0 mi) · Sponsor: Sanofi

See eligibility & contact on ClinicalTrials.gov (NCT07185009)

Paid Clinical Trials in Fayetteville, NC

Studies recruiting near Fayetteville right now

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Empowering Young Parents: Building Healthy Relationships Study

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Shield Post-Approval Study Protocol

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Scheduled or As Needed Pain Regimen?

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Top-rated research centers in Fayetteville

Coastal Research Institute

Cumberland Research Associates

Clinical Counseling and Consulting Services, PLLC Assessment and Treatment Center

North Carolina Clinical Research

Superior Clinical Research, LLC

Duke Clinical Research Institute

M3 Wake Research Raleigh

Rose Research Center

UNC CTRC (Clinical & Translational Research Center)

Clinical trials in Fayetteville: what's recruiting

How to enroll in a paid study in Fayetteville

Frequently asked questions

Paid clinical trials near Fayetteville

More of NC

New paid studies open every week